selected publications
- Genomic Alterations and Associated Outcomes in Patients with PSMA-Positive Metastatic Castration-Resistant Prostate Cancer treated with 177Lu-PSMA-617. The oncologist. 2025 Academic Article GET IT
- Genomic alterations in the YAP/TAZ pathway are associated with stem cell-like castration-resistant prostate cancer. 2025 GET IT
- A complex phylogeny of lineage plasticity in metastatic castration resistant prostate cancer. NPJ precision oncology. 2025 Academic Article GET IT
-
Salivary toxicity from PSMA-targeted radiopharmaceuticals: What we have learned and where we are going.
Cancer treatment reviews.
2024
Review
GET IT
Times cited: 13 -
Prostate-Specific Membrane Antigen-Targeting Alpha Emitter via Antibody Delivery for Metastatic Castration-Resistant Prostate Cancer: A Phase I Dose-Escalation Study of 225Ac-J591.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
2023
Academic Article
GET IT
Times cited: 36 -
Randomized phase II trial of MRI-guided salvage radiotherapy for prostate cancer in 4 weeks versus 2 weeks (SHORTER).
BMC cancer.
2023
Academic Article
GET IT
Times cited: 7 - Long-molecule scars of backup DNA repair in BRCA1- and BRCA2-deficient cancers. Nature. 2023 Academic Article GET IT
-
Prognostic value of neutrophil-to-lymphocyte ratio in patients with metastatic castration-resistant prostate cancer receiving prostate-specific membrane antigen targeted radionuclide therapy.
The Prostate.
2023
Academic Article
GET IT
Times cited: 9 -
Antibody-drug conjugates for urothelial carcinoma.
Urologic oncology.
2023
Review
GET IT
Times cited: 14 -
Complex implementation factors demonstrated when evaluating cost-effectiveness and monitoring racial disparities associated with [18F]DCFPyL PET/CT in prostate cancer men.
Scientific reports.
2023
Academic Article
GET IT
Times cited: 8 -
The Impact of Androgen Deprivation Therapy on COVID-19 Illness in Men With Prostate Cancer.
JNCI cancer spectrum.
2022
Academic Article
GET IT
Times cited: 9 -
Emerging Prostate-specific Membrane Antigen-based Therapeutics: Small Molecules, Antibodies, and Beyond.
European urology focus.
2021
Review
GET IT
Times cited: 1 -
Platinum-Based Chemotherapy in Metastatic Prostate Cancer With DNA Repair Gene Alterations.
JCO precision oncology.
2020
Academic Article
GET IT
Times cited: 122 -
An evaluation of the efficacy and safety of erdafitinib for the treatment of bladder cancer.
Expert opinion on pharmacotherapy.
2020
Review
GET IT
Times cited: 9 -
Infantile Pasteurella multocida meningitis.
2016
GET IT
Times cited: 2 -
Alterations in cancer cell mechanical properties after fluid shear stress exposure: a micropipette aspiration study.
Cell health and cytoskeleton.
2015
Academic Article
GET IT
Times cited: 67 -
Prolyl-4-hydroxylase 3 (PHD3) expression is downregulated during epithelial-to-mesenchymal transition.
PloS one.
2013
Academic Article
GET IT
Times cited: 9 -
Resistance to fluid shear stress is a conserved biophysical property of malignant cells.
PloS one.
2012
Academic Article
GET IT
Times cited: 160 -
Epithelial-to-mesenchymal transition in prostate cancer: paradigm or puzzle?.
Nature reviews. Urology.
2011
Review
GET IT
Times cited: 180